Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

Published version of a preprint

Abstract

Adoptive immunotherapy using autologous T cells endowed with chimeric antigen receptors (CAR) has emerged as a powerful means of treating cancer. However, a limitation of this approach is that autologous CAR T cells must be generated on a custom-made basis. Here we show that electroporation of transcription activator–like effector nuclease (TALEN) mRNA allows highly efficient multiplex gene editing in primary human T cells. We use this TALEN-mediated editing approach to develop a process for the large-scale manufacturing of T cells deficient in expression of both their αβ T-cell receptor (TCR) and CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent. Functionally, T cells manufactured with this process do not mediate graft-versus-host reactions and are rendered resistant to destruction by alemtuzumab. These characteristics enable the administration of alemtuzumab concurrently or prior to engineered T cells, supporting their engraftment. Furthermore, endowing the TALEN-engineered cells with a CD19 CAR led to efficient destruction of CD19+ tumor targets even in the presence of the chemotherapeutic agent. These results demonstrate the applicability of TALEN-mediated genome editing to a scalable process, which enables the manufacturing of third-party CAR T-cell immunotherapies against arbitrary targets. As such, CAR T-cell immunotherapies can therefore be used in an “off-the-shelf” manner akin to other biologic immunopharmaceuticals. Cancer Res; 75(18); 3853–64. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-3321

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 623

Metadata

Authors
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G. W.-K., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A. M., & Smith, J.
Affiliations
  • 1Cellectis, Paris, France.
  • University College London (GB)
  • 2Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom.
  • University of Washington (US)
Venue
Cancer Research
Published
2015-09-14
Volume
75
Issue
18
Pages
3853-3864
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1839053269
Cited by
605
References
45
Citations by year
2026: 32 · 2025: 37 · 2024: 57 · 2023: 62 · 2022: 67 · 2021: 73 · 2020: 79 · 2019: 57 · 2018: 36 · 2017: 51 · 2016: 45 · 2015: 8
FWCI
20.38
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • American Association for Cancer Research
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CAR T-cell therapy, multiplex genome editing, graft-versus-host disease prophylaxis, CD19 CAR, T cell manufacturing
MeSH terms
CD52 Antigen, Alemtuzumab, Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Base Sequence, Cytotoxicity, Immunologic, Drug Resistance, Glycoproteins, Graft vs Host Disease, Humans, Lymphocyte Activation, Lymphoma, Mice, Mutant Strains, Molecular Sequence Data, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, RNA, Messenger, T-Lymphocytes, Transfection, Antigens, CD, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell, alpha-beta, Antigens, CD19, Xenograft Model Antitumor Assays, Mice, Gene Knockout Techniques, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3321
The paper
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G. W.-K., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A. M., & Smith, J. (2015). Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.